{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T21:32:22Z","timestamp":1792099942671,"version":"4.4.0"},"reference-count":9,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2022,11,25]],"date-time":"2022-11-25T00:00:00Z","timestamp":1669334400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,2,22]]},"abstract":"<jats:p>First report of alopecia areata responding to the selective JAK1 inhibitor filgotinib. This case is a patient with coinciding Crohn\u2019s disease that had failed multiple biologics. It serves as a real-world example of how shared decision making between physicians can greatly improve patient outcomes. It highlights that sharing patient registry datasets between specialties will have great benefits, for example in repurposing of JAK inhibitors for other conditions.<\/jats:p>","DOI":"10.1093\/bjd\/ljac103","type":"journal-article","created":{"date-parts":[[2023,1,20]],"date-time":"2023-01-20T14:19:55Z","timestamp":1674224395000},"page":"442-443","source":"Crossref","is-referenced-by-count":6,"title":["Cross-specialty identification of the JAK1 inhibitor trial agent filgotinib as a potential therapy for alopecia areata"],"prefix":"10.1093","volume":"188","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7283-6171","authenticated-orcid":false,"given":"Nicole","family":"Fagan","sequence":"first","affiliation":[{"name":"St James\u2019s Hospital , Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4384-5049","authenticated-orcid":false,"given":"Glen A","family":"Doherty","sequence":"additional","affiliation":[{"name":"St. Vincent\u2019s University Hospital , Dublin , Ireland"},{"name":"Department of Medicine, University College Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9466-6337","authenticated-orcid":false,"given":"Nekma\u00a0","family":"Meah","sequence":"additional","affiliation":[{"name":"St Helens and Knowsley Teaching Hospitals NHS Trust , St Helens , UK"},{"name":"Faculty of Biology, Medicine and Health, The University of Manchester , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6751-1428","authenticated-orcid":false,"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[{"name":"Sinclair Dermatology , Melbourne , Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0107-4488","authenticated-orcid":false,"given":"Dmitri\u00a0","family":"Wall","sequence":"additional","affiliation":[{"name":"Charles Institute of Dermatology, UCD School of Medicine, University College Dublin , Dublin , Ireland"},{"name":"Hair Restoration Blackrock , Blackrock, Dublin , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,11,25]]},"reference":[{"key":"2023100620082266100_ljac103-B1","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1080\/17512433.2020.1702878","article-title":"JAK inhibition in the treatment of alopecia areata \u2013 a promising new dawn?","volume":"13","author":"Ismail","year":"2020","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2023100620082266100_ljac103-B2","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1038\/nm.3645","article-title":"Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition","volume":"20","author":"Xing","year":"2014","journal-title":"Nat Med"},{"key":"2023100620082266100_ljac103-B3","doi-asserted-by":"crossref","first-page":"e85-e86","DOI":"10.1097\/DER.0000000000000780","article-title":"Dual efficacy of upadacitinib in 2 patients with concomitant severe atopic dermatitis and alopecia areata","volume":"32","author":"Gambardella","year":"2021","journal-title":"Dermatitis"},{"key":"2023100620082266100_ljac103-B4","doi-asserted-by":"crossref","first-page":"691","DOI":"10.2147\/CCID.S309215","article-title":"A comprehensive literature review of JAK inhibitors in treatment of alopecia areata","volume":"14","author":"Dillon","year":"2021","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"2023100620082266100_ljac103-B5","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jaad.2020.03.004","article-title":"The Alopecia Areata Consensus of Experts (ACE) study: results of an international expert opinion on treatments for alopecia areata","volume":"83","author":"Meah","year":"2020","journal-title":"J Am Acad Dermatol"},{"key":"2023100620082266100_ljac103-B6","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1002\/art.40186","article-title":"Efficacy, safety, pharmacokinetics, and pharmacodynamics of filgotinib, a selective JAK-1 inhibitor, after short-term treatment of rheumatoid arthritis: results of two randomized phase IIa trials","volume":"69","author":"Vanhoutte","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"2023100620082266100_ljac103-B7","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.4049\/jimmunol.1201348","article-title":"Preclinical characterization of GLPG0634, a selective inhibitor of JAK1, for the treatment of inflammatory diseases","volume":"191","author":"Van Rompaey","year":"2013","journal-title":"J Immunol"},{"key":"2023100620082266100_ljac103-B8","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1001\/jama.2019.9055","article-title":"Effect of filgotinib vs placebo on clinical response in patients with moderate to severe rheumatoid arthritis refractory to disease-modifying antirheumatic drug therapy: the FINCH 2 randomized clinical trial","volume":"322","author":"Genovese","year":"2019","journal-title":"JAMA"},{"key":"2023100620082266100_ljac103-B9","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1001\/jamadermatol.2020.5839","article-title":"A global eDelphi exercise to identify core domains and domain items for the development of a Global Registry of Alopecia Areata Disease Severity and Treatment Safety (GRASS)","volume":"157","author":"Wall","year":"2021","journal-title":"JAMA Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljac103\/48807489\/ljac103.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/3\/442\/51919052\/ljac103.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/188\/3\/442\/51919052\/ljac103.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,6]],"date-time":"2023-10-06T20:14:06Z","timestamp":1696623246000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/188\/3\/442\/6847255"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,25]]},"references-count":9,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,11,25]]},"published-print":{"date-parts":[[2023,2,22]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljac103","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,3,1]]},"published":{"date-parts":[[2022,11,25]]}}}